Description
Linagliptin works by inhibiting dipeptidyl peptidase 4 (DPP-4) which inactivates the incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide, thus prolonging incretin activity in response to ingestion of food. This increases insulin sensitivity, decreases glucagon secretion and improves pancreatic beta cell function.
Linagliptin stimulates the release of insulin and decrease the levels of glucagon in the circulation; is prescribed for type 2 diabetes.
